Table 2.

Transplantation outcome

	No. patients affected/no. evaluable patients (%)
Parameter	HLA-identical	HLA-nonidentical
Early deaths, before day 21	5/62 (8)	1/25 (4)
Sustained engraftment	56/57 (99)	22/25 (88)
GVHD
Acute, grades II-IV	40/57 (70)	18/24 (75)
Chronic*	25/48 (52)	12/21 (57)
Overall survival	38/62 (61)	11/25 (44)
Survival by regimen
CY + ATG + TBI
–3 × 200 cGy	4/8 (50)	2/6 (33)
–2 × 200 cGy	6/12 (50)	3/6 (50)
–1 × 200 cGy	23/35 (66)	5/11 (45)
CY + TBI (6 × 200)	5/7 (71)	0/2 (0)

Median follow-up was 7 years (range, 1.2-10.2 years)

^*Chronic GVHD requiring therapy